4.6 Article

Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency

Journal

JOURNAL OF CLINICAL IMMUNOLOGY
Volume 42, Issue 8, Pages 1626-1637

Publisher

SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s10875-022-01319-0

Keywords

Common variable immunodeficiency; hepatopathy; portal hypertension; diagnosis; nodular regenerative hyperplasia

Categories

Funding

  1. Deutsche Forschungsgemeinschaft [SFB 1160 IMPATH]
  2. EU [634413, 777377]
  3. Projekt DEAL

Ask authors/readers for more resources

Portal hypertension, a manifestation in some CVID patients, is usually not associated with liver cirrhosis. Spleen enlargement and elevated liver stiffness have been identified as markers for further evaluation of portal hypertension in CVID, but better liquid biomarkers are needed for diagnosing this serious complication.
Timely detection of portal hypertension as a manifestation in a subgroup of patients with common variable immunodeficiency (CVID) represents a challenge since it is usually not associated with liver cirrhosis. To identify relevant markers for portal hypertension, we evaluated clinical history, laboratory parameters, and abdominal ultrasound including liver elastography and biomarkers of extracellular matrix formation. Twenty seven (6%) of 479 CVID patients presented with clinically significant portal hypertension as defined by either the presence of esophageal varices or ascites. This manifestation occurred late during the course of the disease (11.8 years after first diagnosis of CVID) and was typically part of a multiorgan disease and associated with a high mortality (11/27 patients died during follow up). The strongest association with portal hypertension was found for splenomegaly with a longitudinal diameter of > 16 cm. Similarly, most patients presented with a liver stiffness measurement (LSM) of above 6.5 kPa, and a LSM above 20 kPa was always indicative of manifest portal hypertension. Additionally, many laboratory parameters including Pro-C4 were significantly altered in patients with portal hypertension without clearly increasing the discriminatory power to detect non-cirrhotic portal hypertension in CVID. Our data suggest that a spleen size above 16 cm and an elevated liver stiffness above 6.5 kPa should prompt further evaluation of portal hypertension and its sequelae, but earlier and better liquid biomarkers of this serious secondary complication in CVID are needed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available